Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 819 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Improving cancer care for the LGBTQ+ community July 26, 2021 ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December December 2, 2024 NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... November 18, 2025 Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... January 20, 2021 Load more HOT NEWS Emma Stone Motivated to Help Others After Her Mother Was Diagnosed... Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to...
